Trials / Terminated
TerminatedNCT02454075
YF476 and Type II Gastric Carcinoids
A Pilot Trial of YF476, a Gastrin Antagonist, in Patients With Type II Gastric Carcinoids Associated With Zollinger-Ellison Syndrome
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 3 (actual)
- Sponsor
- Trio Medicines Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate whether treatment with YF476 is safe and effective in reducing the size of type II gastric carcinoid tumours, or limiting the abnormal growth of gastric ECL cells, in patients with Zollinger-Ellison syndrome.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | YF476 | Gastrin receptor antagonist |
Timeline
- Start date
- 2011-04-11
- Primary completion
- 2012-06-22
- Completion
- 2012-06-22
- First posted
- 2015-05-27
- Last updated
- 2021-01-29
- Results posted
- 2021-01-29
Source: ClinicalTrials.gov record NCT02454075. Inclusion in this directory is not an endorsement.